Celine Halioua

Celine Halioua is the Founder and CEO of Loyal, a biotech company focused on developing drugs to extend the lifespan and improve the health of dogs. Established in 2019, Loyal aims to create the first FDA-approved drug for lifespan extension in any species, starting with canines. Halioua leads a multidisciplinary team that includes neuroscientists, veterinarians, and regulatory experts to achieve this goal.123

Halioua's academic background includes a Bachelor of Science in Neuroscience from the University of Texas at Austin and a D.Phil. (incomplete) from the University of Oxford, where she studied the economics of gene therapy. Before founding Loyal, she served as Chief of Staff at The Longevity Fund, a venture capital firm investing in longevity-related therapies.234

Since its inception, Loyal has raised over $125 million from prominent venture capitalists, including Khosla Ventures and Bain Capital. Halioua's vision extends beyond dogs; she believes that the advancements made through her company could eventually benefit human health as well.23